Khan Shamima S, Mican Lisa M
Austin Psychiatry Residency Program, Child and Adolescent Psychiatry Services, Austin State Hospital, Austin, Texas, USA.
J Child Adolesc Psychopharmacol. 2006 Dec;16(6):671-7. doi: 10.1089/cap.2006.16.671.
The aim of this study was to compare the efficacy and safety of intramuscular ziprasidone versus intramuscular (i.m.) olanzapine in treating aggression in youth.
A retrospective chart review of 100 hospitalized patients less than 18 years of age treated with either i.m. ziprasidone or i.m. olanzapine for agitation or aggression was conducted. Comparisons were performed using statistical analysis of data collected from medical records.
Baseline demographics were similar in the i.m. olanzapine and ziprasidone treatment groups regarding age and ethnicity; however, gender differences did reach statistical significance (p < 0.001). Dosing between children and adolescents significantly differed in the olanzapine group, whereas dosing was comparable in the ziprasidone group. No significant differences between the olanzapine and ziprasidone treatment groups were noted regarding length of stay, efficacy of the study medications, number of restraints, and duration of restraints. Ziprasidone subjects received significantly more doses of emergency medication during their hospital stay and significantly more doses of ziprasidone were administered with concomitant lorazepam or antihistamines.
The results suggest i.m. ziprasidone and intramuscular olanzapine may be equally effective in treating aggression in youth. These agents may also be similar with regard to safety because no clinically significant adverse events were reported for either treatment group. The possibility of poor documentation of adverse events and side effects prevents formulating definitive conclusions regarding safety from this study.
本研究旨在比较肌内注射齐拉西酮与肌内注射奥氮平治疗青少年攻击行为的疗效和安全性。
对100例18岁以下因激越或攻击行为接受肌内注射齐拉西酮或肌内注射奥氮平治疗的住院患者进行回顾性病历审查。使用从病历中收集的数据进行统计分析以进行比较。
肌内注射奥氮平和齐拉西酮治疗组在年龄和种族方面的基线人口统计学特征相似；然而，性别差异具有统计学意义（p < 0.001）。奥氮平组儿童和青少年的给药剂量有显著差异，而齐拉西酮组的给药剂量相当。在住院时间、研究药物疗效、约束次数和约束持续时间方面，奥氮平和齐拉西酮治疗组之间未观察到显著差异。齐拉西酮组患者在住院期间接受的急救药物剂量显著更多，并且齐拉西酮与劳拉西泮或抗组胺药联合使用的剂量也显著更多。
结果表明，肌内注射齐拉西酮和肌内注射奥氮平在治疗青少年攻击行为方面可能同样有效。由于两个治疗组均未报告具有临床意义的不良事件，这些药物在安全性方面可能也相似。不良事件和副作用记录不佳的可能性妨碍了从本研究中得出关于安全性的明确结论。
